// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























41730 Abstracts

SHP-1 determines the radiosensitivity of liver cancer cell and dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma via targeting SHP-1/STAT3 signaling

Man-Hsin Hung - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dovitinib

Preclinical evaluation of the CDK4/6 inhibitor LEE011 in nasopharyngeal carcinoma (NPC) cell lines

Brigette B. Ma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Mutated cancer cell-specific cell death activity of alkylating Pyrrole-Imidazole polyamide conjugates targeting a variety of oncogenic driver gene mutations

Hiroki Nagase - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Mechanistic evaluation of AG311 - an OXPHOS inhibitor - as a potential treatment for breast cancer

Anja Bastian - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dichloroacetate

Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma

Lan Wei - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Development of a dual inhibitor of pan-RAF and VEGFR2 for the treatment of metastatic colorectal cancer with mutant K-RAS

Sungpyo Hong - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Targeting cholesterol biosynthesis pathway to inhibit growth of drug resistant ovarian cancer cells

Yayun Liang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

TRPV6 calcium channel peptide antagonists as novel antimyeloma and antiresorptive agents

Alli Murugesan - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Solid malignancies

SOR-C13

Cell-based, high-throughput screen for small molecule inducers of cell death in HPV-associated head and neck cancers

Nene N. Kalu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Palbociclib

Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Patrizia Carpinelli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Targeting cancer stem cells using ALDH-dependent 5-nitrofuran prodrugs

Richard Crispin - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A glycan-binding malaria protein provides therapeutic access to cisplatin-resistant bladder cancer

HTOO ZARNI OO - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

The PAK4 allosteric modulator (KPT-9274) attenuates the growth of renal cell carcinoma

Robert H. Weiss - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Solid malignancies

N/A

Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer

Masaomi Kuwada - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Structural changes to SN79 result in ligands that stimulate a metabolic function of sigma-2 receptors

Hilary Elaine Nicholson - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phosphaplatins are potent inducers of pigment epithelial- derived factor (PEDF)

Louiza Belkacemi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Histone deacetylase inhibitors repress hypoxia signaling through affecting Hsp90

Chunzhang Yang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vorinostat

The mechanobiome of pancreatic ductal adenocarcinoma: a new, targetable drug space

Alexandra Surcel - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

FAK inhibition resensitizes platinum-resistant serous ovarian cancer

Lisa M. Bean - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Cyclin-dependent kinase 9: a potential therapeutic target for esophageal adenocarcinoma

Zhimin Tong - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Copyright © 2026. QuantiNova All rights reserved